Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

The issues for the legal community are twofold. First, what are the potential responsibilities of the patient’s physician?

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

The noninferiority trial included 234 adults (five lost to follow-up) who were referred to seven sites across the U.S. for ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.

In a 2014 Nature paper, Ralston described this awkward process — trogocytosis, or “cell nibbling.” It was a revelation at the ...